How CAR T-Cell Therapy Enabled Kidney Transplants for Highly Sensitized Patients

This episode explains how a novel CAR T-cell approach made kidney transplantation possible for patients previously considered unmatched, and why that could change outcomes for people waiting on dialysis. Dr. Vijay Bhoj, MD, PhD, assistant professor of pathology and cellular immunotherapy at the University of Pennsylvania, walks through the phase 1, multi-institutional trial that combined CD19 and BCMA CAR T-cells to achieve durable antibody reduction and successful transplants.

Listen to the Podcast and watch the full vodcast on our YouTube channel for details.

Keywords: CAR T-Cell therapy, kidney transplantation, BCMA, CD19, plasmapheresis.